Manufacturer:
Amgen
Route of Administration:
Intravenous
Site of Care:
Outpatient
Website:
phone:
866-264-2778
Approved Indication:
-
- reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
- reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
- reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
- [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signa and symptoms in adult patients with active ankylosing spondylitis
- reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
- treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology